| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000038020 |
| Receipt No. | R000043324 |
| Scientific Title | Verification of effects of test food intake |
| Date of disclosure of the study information | 2020/03/31 |
| Last modified on | 2020/12/22 (Ver. 2) |
| Basic information | ||
| Public title | Verification of effects of test food intake | |
| Acronym | Verification of effects of test food intake | |
| Scientific Title | Verification of effects of test food intake | |
| Scientific Title:Acronym | Verification of effects of test food intake | |
| Region |
|
|
| Condition | ||
| Condition | N/A(healthy adults) | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | This study aims to examine effects of test food for physical function. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Motor function, daily activity, body composition, questionnaire evaluation |
| Key secondary outcomes | Oxidative stress index |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test food for 12 weeks | |
| Interventions/Control_2 | Ingestion of placebo for 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Japanese individuals aged 50-79 years.
2) Individuals who are healthy and are not suffered from a chronic malady. 3) Individuals whose ADL questionnaire scores is higher than 12. 4) Non-smoker 5) Individuals whose BMI scores is not less than 22.5 kg/m2 and less than 30.0 kg/m2. 6) Individulals who can visit an inspection facility and be inspected in designated days. 7) Individuals whose written informed consent has been obtained. |
|||
| Key exclusion criteria | 1) Those who meet the criteria of sarcopenia from the results of grip strength and gait speed (Male subjects whose grip strength values are less than 26.0kg and gait speed is less than 0.8 m/s. Female subjects whose grip strength values are less than 18.0kg and gait speed is less than 0.8m/s.)
2) Individuals who have been hospitalized with joint pains such as knees and lower back within 3 months 3) Individuals who is allergic to test food 4) Individuals with a large history of surgery on the gastrointestinal tract, such as gastrectomy, gastrointestinal suture, and intestinal resection 5) Individuals who have difficulty in participating in the study due to liver disease, kidney disease, heart disease, respiratory disorder, endocrine disorder, metabolic disorder, neurological disorder, consciousness disorder, diabetes, and other diseases 6) Individuals with a history of serious cardiovascular disease 7) Individuals who regularly use amino acid, protein-reinforced foods or beverages for the purpose of maintaining physical fitness, improving motor function or dieting 8) Individuals who regularly use medicines and supplements that may affect this study (However, those who can suspend intake at the time of the test are not applicable) 9) Individuals who have experienced bad mood or poor physical condition due to blood sampling in the past 10) Individuals who donated blood more than 200mL between the month before the start of the test, or who is scheduled to do so during the test period 11) Individuals who participated in other clinical studies in the past 4 weeks. 12) Individuals who drink a lot of alcohol 13) Individuals who have extremely irregular eating habits 14) Irregular shift workers 15) Individuals who do not agree with the purpose of the explanation of this examination 16) Individuals judged inappropriate for the study by the principal. |
|||
| Target sample size | 24 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Akanuma Surgery Clinic | ||||||
| Division name | Department | ||||||
| Zip code | 005-0842 | ||||||
| Address | 14-1, Isiyama2-jo 6, Minami-ku Sapporo-shi, Hokkaido | ||||||
| TEL | 011-200-9431 | ||||||
| y-kohzai@kyowa-t.com | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kyowa Trial Co., Ltd. | ||||||
| Division name | Clinical Trials Division | ||||||
| Zip code | 064-0923 | ||||||
| Address | 1-40, minami 23-jo nisi 11-tyoume, tyuuou-ku Sapporo-shi, Hokkaido | ||||||
| TEL | 011-200-9431 | ||||||
| Homepage URL | https://www.kyowa-t.com/ | ||||||
| y-kohzai@kyowa-t.com | |||||||
| Sponsor | |
| Institute | Akanuma Surgery Clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Morinaga & Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Akanuma surgery clinic ethics review board |
| Address | 14-1, Isiyama2-jo 6, Minami-ku Sapporo-shi, Hokkaido |
| Tel | 011-200-9431 |
| y-kohzai@kyowa-t.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043324 |